Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 230

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Antimicrobial Peptides, Innate Immunity, and the Normally Sterile Urinary Tract

Zasloff, Michael · 2007 · Journal of the American Society of Nephrology

Abstract

Abstract Background Group B Streptococcus (GBS) can cause invasive disease (iGBS) in young infants, typically presenting as sepsis or meningitis, and is also associated with stillbirth and preterm birth. GBS vaccines are under development, but their potential health impact and cost-effectiveness have not been assessed globally. Methods We assessed the health impact and value (using net monetary benefit, NMB, which measures both health and economic effects of vaccination into monetary units), of GBS maternal vaccination across 183 countries in 2020. Our analysis uses a decision-tree model, combining risks of GBS-related outcomes from a Bayesian disease burden model with estimates of GBS related costs and Quality-Adjusted Life Years (QALYs) lost. We assumed 80% vaccine efficacy against iGBS and stillbirth, following the WHO Preferred Product Characteristics, and coverage based on the proportion of pregnant women receiving at least four antenatal visits. One dose was assumed to cost $50 in high-income countries, $15 in upper-middle income countries, and $3.50 in low-/lower-middle income countries. We estimated NMB using alternative normative assumptions that may be adopted by policy makers. Findings Vaccinating pregnant women could avert 214,000 (95% uncertainty range 151,000 – 457,000) infant iGBS cases, 31,000 deaths (14,000 – 67,000), 21,000 (9,000 – 52,000) cases of neurodevelopmental impairment, and 23,000 (10,000 – 58,000) stillbirths. A vaccine effective against GBS-associated prematurity might also avert 172,000 (13,000 – 378,000) preterm births. Globally, a 1-dose vaccine programme could cost $1.7 billion but save $385 million in healthcare costs. Estimated global NMB ranged from $1.1 billion ($-0.2 – 3.8 billion) to $17 billion ($9.1 – 31 billion). Interpretation Maternal GBS vaccination could have a large impact on infant morbidity and mortality globally and at reasonable prices is likely to be cost-effective.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1681/asn.2007050611

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Cited by

See all 230

Metadata

Authors
Zasloff, M.
Venue
Journal of the American Society of Nephrology
Published
2007-11
Volume
18
Issue
11
Pages
2810-2816
ISSN
1046-6673 (ISSN-L)
OpenAlex
W2117914067
Cited by
230
References
10
FWCI
8.64
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Antimicrobial Peptides, Innate Immunity, and the Normally Sterile Urinary Tract. https://app.cochat.ai/papers/10.1681/asn.2007050611
The paper
Zasloff, M. (2007). Antimicrobial Peptides, Innate Immunity, and the Normally Sterile Urinary Tract. Journal of the American Society of Nephrology. https://doi.org/10.1681/asn.2007050611

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.